← Back to patent-cliff list
CAS 6066-82-6
1-Hydroxy-2,5-pyrrolidinedioneN-Hydroxysuccinimide
Codes: (V)101438-62-a, Enalapril-030, Atosiban-026
Application context (from source-drug indications)
Breast cancerPaclitaxel/Encequidar mesylateAdenocarcinomaPaclitaxel/Encequidar mesylateAngiosarcomaPaclitaxel/Encequidar mesylateSolid tumourPaclitaxel/Encequidar mesylateCardiac and vascular disordersAtorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilHypertensionAtorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilHyperlipidaemiaAtorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilHeart diseaseAtorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilEssential hypertensionEnalapril Maleate/Folic AcidHeart failureEnalapril MaleateHypertensionEnalapril MaleateMyocardial infarctionEnalapril MaleateAngina pectorisEnalapril MaleateLeft ventricular dysfunctionEnalapril MaleateSolid tumourEnalapril MaleatePancreatic cancerPaclitaxelNon-small cell lung cancerPaclitaxelHodgkin's diseasePaclitaxelSeminomaPaclitaxelOvarian cancerPaclitaxelBreast cancerPaclitaxel产科分娩（早产）Atosiban acetate早产（孕37周前）Atosiban acetateEndometriosisAtosiban acetate
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Paclitaxel/Encequidar mesylate | Tier C — Watch / trade | - |
| Atorvastatin/Hydrochlorothiazide/Aspirin/Enalapril | Tier C — Watch / trade | - |
| Enalapril Maleate/Folic Acid | Tier C — Watch / trade | - |
| Enalapril Maleate | Tier C — Watch / trade | - |
| Paclitaxel | Tier B — Position early | - |
| Atosiban acetate | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
Dihydroxyacetic acid→4-Methylbenzenesulfonhydrazide→(2E)-[2-(4-Methylbenzene-1-sulfonyl)hydrazinylidene]acetic acid→(2E)-[2-(4-Methylbenzene-1-sulfonyl)hydrazinylidene]acetyl chloride→Benzaldehyde→1-Hydroxy-2,5-pyrrolidinedione→2,5-Dioxopyrrolidin-1-yl 2-diazoacetate→1-Aminobutane→N-Butyl-2-diazoacetamide→(2R,3R)-N-Butyl-3-phenyloxirane-2-carboxamide→tert-Butyl butyl[(2R,3R)-3-phenyloxirane-2-carbonyl]carbamate→Ethyl (2R,3R)-3-phenyloxirane-2-carboxylate→Ethyl (2R,3S)-3-azido-2-hydroxy-3-phenylpropanoate→alpha-Chlorobenzaldehyde→(1S,2R)-1-Azido-3-ethoxy-3-oxo-1-phenylpropan-2-yl benzoate→Ethyl (2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoate
Atorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilOptimised routesteps: 6total yield: 174mg(Enalapril-033)
(2-Bromoethyl)benzene→Bromido(2-phenylethyl)magnesium→Oxalic acid diethyl diester→2-Oxo-4-phenylbutyric acid ethyl ester→4,5-Ditritium-L-proline→L-Alanine→N-(1-Ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanine→N-Hydroxysuccinimide→Ethyl 2-([(2S)-1-[(2,5-dioxopyrrolidin-1-yl)oxy]-1-oxopropan-2-yl]amino)-4-phenylbutanoate→N-(1-Ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl-4,5-ditritium-L-proline→(2Z)-But-2-enedioic acid N-[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]-L-alanyl-4,5-ditritium-L-proline
(2-Bromoethyl)benzene→Bromido(2-phenylethyl)magnesium→Oxalic acid diethyl diester→2-Oxo-4-phenylbutyric acid ethyl ester→4,5-Ditritium-L-proline→L-Alanine→N-(1-Ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanine→N-Hydroxysuccinimide→Ethyl 2-([(2S)-1-[(2,5-dioxopyrrolidin-1-yl)oxy]-1-oxopropan-2-yl]amino)-4-phenylbutanoate→N-(1-Ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl-4,5-ditritium-L-proline→(2Z)-But-2-enedioic acid N-[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]-L-alanyl-4,5-ditritium-L-proline
(2-Bromoethyl)benzene→Bromido(2-phenylethyl)magnesium→Oxalic acid diethyl diester→2-Oxo-4-phenylbutyric acid ethyl ester→4,5-Ditritium-L-proline→L-Alanine→N-(1-Ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanine→N-Hydroxysuccinimide→Ethyl 2-([(2S)-1-[(2,5-dioxopyrrolidin-1-yl)oxy]-1-oxopropan-2-yl]amino)-4-phenylbutanoate→N-(1-Ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl-4,5-ditritium-L-proline→(2Z)-But-2-enedioic acid N-[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]-L-alanyl-4,5-ditritium-L-proline
Dihydroxyacetic acid→4-Methylbenzenesulfonhydrazide→(2E)-[2-(4-Methylbenzene-1-sulfonyl)hydrazinylidene]acetic acid→(2E)-[2-(4-Methylbenzene-1-sulfonyl)hydrazinylidene]acetyl chloride→Benzaldehyde→1-Hydroxy-2,5-pyrrolidinedione→2,5-Dioxopyrrolidin-1-yl 2-diazoacetate→1-Aminobutane→N-Butyl-2-diazoacetamide→(2R,3R)-N-Butyl-3-phenyloxirane-2-carboxamide→tert-Butyl butyl[(2R,3R)-3-phenyloxirane-2-carbonyl]carbamate→Ethyl (2R,3R)-3-phenyloxirane-2-carboxylate→Ethyl (2R,3S)-3-azido-2-hydroxy-3-phenylpropanoate→alpha-Chlorobenzaldehyde→(1S,2R)-1-Azido-3-ethoxy-3-oxo-1-phenylpropan-2-yl benzoate→Ethyl (2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoate
S-Benzyl-N-(tert-butoxycarbonyl)-L-cysteine→1-Hydroxy-2,5-pyrrolidinedione→2,5-Dioxopyrrolidin-1-yl S-benzyl-N-(tert-butoxycarbonyl)-L-cysteinate→Pyrrolidine-2(S)-carboxylic acid→N2-(tert-Butoxycarbonyl)-L-asparaginyl-S-benzyl-L-cysteinyl-L-proline→S-Benzyl-N-(tert-butoxycarbonyl)-L-cysteinyl-L-proline→S-Benzyl-L-cysteinyl-L-proline→2,5-Dioxopyrrolidin-1-yl N2-(tert-butoxycarbonyl)-L-asparaginate→N2-(tert-Butoxycarbonyl)-L-asparagine→L-Asparaginyl-S-benzyl-L-cysteinyl-L-proline trifluoroacetate→2,5-Dioxopyrrolidin-1-yl O-benzyl-N-(tert-butoxycarbonyl)-L-threoninate→O-Benzyl-N-(tert-butoxycarbonyl)-L-threonine→O-Benzyl-N-(tert-butoxycarbonyl)-L-threonyl-L-asparaginyl-S-benzyl-L-cysteinyl-L-proline
O-Benzyl-L-threonyl-L-asparaginyl-S-benzyl-L-cysteinyl-L-proline trifluoroacetate→3-(Benzylsulfanyl)-N-[(2R)-3-(4-ethoxyphenyl)-1-hydrazino-1-oxopropan-2-yl]propanamide→2,5-Dioxopyrrolidin-1-yl N-(tert-butoxycarbonyl)-L-isoleucinate→N-(tert-Butoxycarbonyl)-L-isoleucine→N-(tert-Butoxycarbonyl)-L-isoleucyl-O-benzyl-L-threonyl-L-asparaginyl-S-benzyl-L-cysteinyl-L-proline→L-Isoleucyl-O-benzyl-L-threonyl-L-asparaginyl-S-benzyl-L-cysteinyl-L-proline trifluoroacetate→N-[3-(Benzylsulfanyl)propanoyl]-O-ethyl-D-tyrosyl-L-isoleucyl-O-benzyl-L-threonyl-L-asparaginyl-S-benzyl-L-cysteinyl-L-proline→1-Hydroxy-2,5-pyrrolidinedione→O-Benzyl-N-(tert-butoxycarbonyl)-L-threonyl-L-asparaginyl-S-benzyl-L-cysteinyl-L-proline
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.